Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pacing Clin Electrophysiol ; 24(1): 13-5, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11227962

ABSTRACT

The inability to perform telemetry on an ICD may have many potential causes. We report three recently identified cases where such a finding was indicative of unexpected device failure. Two of these cases involved identical failure mechanisms resulting from arcing of current within the high voltage hybrid. This placed the device into a high current state that caused rapid and complete battery depletion. There were no company alerts issued regarding this systematic problem. A multicenter arrhythmia device/lead database would be extremely useful in providing timely and unbiased information concerning device problems.


Subject(s)
Defibrillators, Implantable , Telemetry , Aged , Databases, Factual , Defibrillators, Implantable/statistics & numerical data , Device Removal , Electric Power Supplies , Equipment Failure/statistics & numerical data , Female , Humans , Male , United States , United States Food and Drug Administration
2.
J Am Coll Cardiol ; 28(3): 591-6, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8772744

ABSTRACT

OBJECTIVES: This investigation sought to determine whether endothelium-derived nitric oxide contributes to hypoxia-induced systemic vasodilation and pulmonary vasoconstriction in humans. BACKGROUND: Endothelium-derived nitric oxide contributes to basal systemic and pulmonary vascular resistance. During hypoxia, systemic vasodilation and pulmonary vasoconstriction occur. There are some data indicating that endothelium-derived nitric oxide mediates changes in vascular resistance during hypoxia, but much of it is contradictory, and none has been derived from normal humans. METHODS: The hemodynamic effects of NG-monomethyl-L-arginine (L-NMMA), a nitric oxide synthase inhibitor, were studied in healthy volunteers under normoxic and hypoxic conditions. A Swan-Ganz catheter and radial artery cannula were inserted to measure right atrial, pulmonary artery, pulmonary capillary wedge and systemic blood pressures. Cardiac output was measured by thermodilution. Systemic vascular resistance and pulmonary vascular resistance were calculated. The pharmacokinetics of L-NMMA (300 mg intravenously) was studied during normoxia in six subjects. Hypoxia was induced in eight subjects who inspired a mixture of nitrogen and oxygen through a gas blender adjusted to reduce the partial pressure of oxygen from (mean +/- SE) 98 +/- 4 to 48 +/- 1 mm Hg. RESULTS: During normoxia, L-NMMA increased systemic vascular resistance from 1,108 +/- 74 to 1,705 +/- 87 dynes-s-cm-5 and increased pulmonary vascular resistance from 60 +/- 5 to 115 +/- 9 dynes-s-cm-5 (p < or = 0.01 for each). Peak effects occurred within 10 min of L-NMMA administration. Acute hypoxia alone decreased systemic vascular resistance from 1,209 +/- 78 to 992 +/- 58 dynes-s-cm-5 (p < or = 0.05) and increased pulmonary vascular resistance from 92 +/- 11 to 136 +/- 4 dynes-s-cm-5 (p < or = 0.01). While hypoxic conditions were maintained, infusion of L-NMMA increased systemic vascular resistance (to 1,496 +/- 97 dynes-s-cm-5, p < or = 0.01) and increased pulmonary vascular resistance further (to 217 +/- 25 dynes-s-cm-5, p < or = 0.01). CONCLUSIONS: Endothelium-derived nitric oxide contributes to systemic vasodilation and serves as a counterregulatory mechanism to attenuate pulmonary vasoconstriction during acute hypoxia in healthy human subjects.


Subject(s)
Hypoxia/physiopathology , Nitric Oxide/physiology , Vascular Resistance/physiology , Acute Disease , Adult , Arginine/analogs & derivatives , Arginine/pharmacokinetics , Arginine/pharmacology , Blood Pressure/drug effects , Female , Hemodynamics/drug effects , Humans , Male , Nitric Oxide Synthase/antagonists & inhibitors , Pulmonary Circulation/drug effects , Pulmonary Circulation/physiology , Vascular Resistance/drug effects , Vasoconstriction/drug effects , Vasoconstriction/physiology , Vasodilation/drug effects , Vasodilation/physiology , omega-N-Methylarginine
3.
Am J Physiol ; 271(3 Pt 2): H1182-5, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8853358

ABSTRACT

Endothelium-derived nitric oxide (EDNO) contributes to basal systemic vascular resistance under normoxic conditions. The purpose of this investigation was to determine whether EDNO contributes to the regulation of limb vascular resistance during hypoxia in healthy humans. Forearm blood flow was assessed by venous occlusion plethysmography. Hypoxia was induced by delivering a mixture of N2 and O2 via a gas blender adjusted to reduce the PO2 to 50 mmHg. During hypoxia, forearm blood flow increased from 2.4 +/- 0.2 to 3.0 +/- 0.3 ml.100 ml-1.min-1 (P < 0.001), and forearm vascular resistance decreased from 38 +/- 3 to 29 +/- 3 units (P < 0.001). The nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, 2,000 micrograms/min intra-arterially) was administered to eight subjects. The percent increase in forearm vascular resistance after administration of L-NMMA was greater during hypoxia than normoxia (67 +/- 14 vs. 39 +/- 15%, P < 0.05). L-NMMA reduced the forearm vasodilator response to hypoxia from 27 +/- 3 to 11 +/- 5% (P = 0.01). To exclude the possibility that this attenuated response to hypoxia was a consequence of vasoconstriction and not specific for nitric oxide synthase inhibition, six subjects received intra-arterial phenylephrine. Phenylephrine did not affect the vasodilator response to hypoxia (17 +/- 3 vs. 21 +/- 6%, P = NS). It is concluded that EDNO contributes to hypoxia-induced vasodilation in the forearm resistance vessels in healthy humans.


Subject(s)
Blood Vessels/physiology , Hypoxia/physiopathology , Nitric Oxide/physiology , Vascular Resistance , Vasodilation/physiology , Adult , Enzyme Inhibitors/pharmacology , Female , Forearm/blood supply , Humans , Male , Phenylephrine/pharmacology , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects , omega-N-Methylarginine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...